

一、研究团队简介

广东省人民医院心内科主任荆志成教授课题组长期专注于右心和肺血管疾病的基础、临床和转化研究，包括但不限于肺栓塞、先天性心脏病、右心系统瓣膜、遗传和药物、内分泌和免疫性疾病对右心和肺循环的影响。旨在探索国人相关疾病特征、疾病发生机制，寻找和开发从 0 到 1 的新型诊断、治疗和预防疾病的医疗器械、药物等方法。

现面向海内外诚聘博士后人员若干名，欢迎申请加入本团队！

二、合作导师介绍



荆志成，广东省人民医院心内科主任，广东省医学科学院副院长，主任医师，教授，研究员，博士研究生导师，博士后合作导师。

已获“国家杰出青年科学基金”资助、“长江学者”特聘教授、国家“万人计划”领军人才、百千万人才工程国家级人选暨有突出贡献的中青年专家、首届树兰医学青年奖、北京优秀医师奖、中国医师奖、“吴杨奖”等一系列国家级奖励和荣誉。任中华心血管病杂志副总编辑，中国介入心脏病学杂志执行主编，*中华医学杂志（英文版）*副总

编辑、中华医学会心血管病学分会结构心脏病学组副组长，北京医学会血栓与止血分会主任委员、北京医学会心血管病学分会副主任委员，*Journal of Thrombosis and Haemostasis* 副主编，比利时弗兰德研究基金会(FWO)医学六处专家组成员等国内外学术职务。主持“十三五”“十四五”国家重点研发计划，国家自然科学基金重点专项等国家级科研项目。以第一完成人荣获2022年度中华医学科技奖一等奖、2021年度北京医学科技奖一等奖等科技奖励。

三、课题组主要研究内容

1. 肺循环与先天性心脏病；
2. 肺动脉高压与右心，右心瓣膜，左右心相互作用；
3. 血栓形成，肺栓塞

四、合作导师代表性论著

截止到2023年11月10日，部分英文学术论文代表作：

1. Zhang ZJ, Wang HF, Lian TY, Zhou YP, Xu XQ, Guo F, Wei YP, Li JY, Sun K, Liu C, Pan LR, Ren M, Nie L, Dai HL, **Jing ZC**. Human Plasma IgG N-Glycome Profiles Reveal a Proinflammatory Phenotype in Chronic Thromboembolic Pulmonary Hypertension. *Hypertension*. 2023 Sep;80(9):1929-1939. (IF=8.3, **Co-Corresponding Author**)
2. Wu XH, He YY, Chen ZR, He ZY, Yan Y, He Y, Wang GM, Dong Y, Yang Y, Sun YM, Ren YH, Zhao QY, Yang XD, Wang LY, Fu CJ, He M, Zhang SJ, Fu JF, Liu H, **Jing ZC**. Single-cell analysis of peripheral blood from high-altitude pulmonary hypertension patients identifies a distinct monocyte phenotype. *Nat Commun*. 2023 Mar 31;14(1):1820. (IF=16.6, **Co-Corresponding Author**)

3. Lian TY, Yan Y, Ding D, Ma YJ, Zhang X, *Jing ZC*. Building a modern six-dimensional biobank fosters the future of precision medicine. *Sci Bull (Beijing)*. 2022 Dec 31;67(24):2490-2493. (IF=18.9, Corresponding Author)
4. Wang HF, Wang YX, Zhou YP, Wei YP, Yan Y, Zhang ZJ, *Jing ZC*. Protein O-GlcNAcylation in cardiovascular diseases. *Acta Pharmacol Sin*. 2023 Jan;44(1):8-18. (IF=8.2, Co-Corresponding Author)
5. Liu B, Wei YP, Fan X, Hu X, Chen Z, Liu X, Xu Y, Wang L, Wang T, Ruiz M, Dupuis J, Yuan P, Liu J, Huang S, Zhu L, *Jing ZC*, Hu Q. Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility. *Hypertension* 2022 Apr 28: 101161HYPERTENSIONAHA.121.18399. (IF=10.190, Co-Corresponding Author)
6. Zhou YP, Wei YP, Yang YJ, Xu XQ, Wu T, Liu C, Mei KY, Peng FH, Wang HP, Sun K, Li JY, Wang HF, Li MT, Wang DL, Miao Q, Jiang X, *Jing ZC*. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. *J Am Coll Cardiol*. 2022 Apr 19;79(15):1477-1488. (IF=24.094, Corresponding author)
7. Jiang X, Zhu YJ, Zhou YP, Peng FH, Wang L, Ma W, Cao YS, Pan X, Zhang GC, Zhang F, Fan FL, Wu BX, Huang W, Yang ZW, Hong C, Li MT, Wang YN, Xu XQ, Wang DL, Zhang SY, *Jing ZC*. Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide study. *Eur Heart J*. 2021 Nov 7;42(42):4298-4305. (IF = 29.983, Corresponding author)
8. Lian TY, Lu D, Yan XX, Tan JS, Peng FH, Zhu YJ, Wei YP, Wu T, Sun K, Jiang X, Hua L, *Jing ZC*. Association between congenital thrombophilia and outcomes in pulmonary embolism patients. *Blood Adv*. 2020 Dec 8;4(23):5958-5965. (IF = 6.686, Corresponding author)
9. Yan Y, He YY, Jiang X, Wang Y, Chen JW, Zhao JH, Ye J, Lian TY, Zhang X, Zhang RJ, Lu D, Guo SS, Xu XQ, Sun K, Li SQ, Zhang LF, Zhang X, Zhang SY, *Jing ZC*. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension. *Science Advance*. 2020 Dec 9;6(50):eaba2470. (IF = 14.136, Corresponding author)

10. He YY, Yan Y, Jiang X, Zhao JH, Wang Z, Wu T, Wang Y, Guo SS, Ye J, Lian TY, Xu XQ, Zhang JL, Sun K, Peng FH, Zhou YP, Mao YM, Zhang X, Chen JW, Zhang SY, *Jing ZC*, Spermine promotes pulmonary vascular remodeling and its synthase is a therapeutic target for pulmonary arterial hypertension. *Eur Respir J*. 2020 Nov 5;56(5):2000522. (IF = 16.671, Corresponding author)
11. Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, *Jing ZC*, Liu B, Chen J, Nie S, Zhu J, Li F, Ma C. CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic. *Circulation*. 2020;141(20):e810-816. (IF= 29.690, Guideline Co-Committee member)
12. Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, *Jing ZC*, Koestenberger M, Meinel K, Mocumbi A, Radchenko G, Sallmon H, Sliwa K, Kumar R, on behalf of the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, CSC, PASCAR, PCS, and PCSI. Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions. *J Am Coll Cardiol*. 2020 May 19;75(19):2463-2477. (IF=24.094, Co-author)
13. Zhang J, He Y, Yan X, Shanshan Chen, Ming He, Yuyang Lei, Jiao Zhang, Brendan Gongol, Mingxia Gu, Yifei Miao, Liang Bai, Xiaopei Cui, Xiaojian Wang, Yixin Zhang, Fenling Fan, Zhao Li, Yuan Shen, Chih-Hung Chou, Hsien-Da Huang, Atul Malhotra, Marlene Rabinovitch, *Jing ZC*, John Y-J Shyy. MicroRNA-483 Amelioration of Experimental Pulmonary Hypertension. *EMBO Mol Med*. 2020 May 8;12(5):e11303. (IF=12.137, Co-corresponding Author)
14. Wang XJ, Xu XQ, Sun K, Liu KQ, Li SQ, Jiang X, Zhao QH, Wang L, Peng FH, Ye J, Wu Y, Jiang R, Zhang J, Huang W, Bei WB, Yan Y, Li JH, Liu QQ, Li S, Wang Y, Zhang SY, Zhang X, *Jing ZC*. Association of rare PTGIS variants with susceptibility and pulmonary vascular response in patients with idiopathic pulmonary arterial hypertension. *JAMA Cardiol*. 2020 Apr 1;5(6):677-684. (IF=14.676, Co-corresponding Author)
15. *Jing ZC*, Zhu HD, Yan XW, Chai WZ, Zhang SY, on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital. Recommendations

- from Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. *Eur Heart J*. 2020 Mar 31;41(19):1791-1794. (IF=29.983, First Author)
16. Jiang X, Xu XQ, **Jing ZC**. The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS). *Eur Heart J*. 2019 Dec 21;40(48):3881-3885. (IF=29.983, Corresponding Author)
17. Gu W, Ni Z, Tan YQ, Deng J, Zhang SJ, Lv ZC, Wang XJ, Chen T, Zhang Z, Hu Y, **Jing ZC**, Xu Q. Adventitial Cell Atlas of wt (Wild Type) and ApoE (Apolipoprotein E)-Deficient Mice Defined by Single-Cell RNA Sequencing. *Arterioscler Thromb Vasc Biol*. 2019 Jun;39(6):1055-1071. (IF=8.311, Co-corresponding Author)
18. Galiè N, Channick RN, Frantz RP, Grünig E, **Jing ZC**, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Respir J*. 2019 Jan 24;53(1):1801889. (IF=16.671, Co Committee-member, Proceedings of the 6th World Symposium on Pulmonary Hypertension)
19. Wang XJ, Lian TY, Jiang X, Liu SF, Li SQ, Jiang R, Wu WH, Ye J, Cheng CY, Du Y, Xu XQ, Wu Y, Peng FH, Sun K, Mao YM, Yu H, Liang C, John YJ, Zhang SY, Zhang X, **Jing ZC**. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2019 Mar 14;53(3):1801609. (IF=16.671, Corresponding Author)
20. Wu WH, Yuan P, Zhang SJ, Jiang X, Wu C, Li Y, Liu SF, Liu QQ, Li JH, Pudasaini B, Hu QH, Dupuis J, **Jing ZC**. Impact of Pituitary–Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men. *Hypertension*. 2018 Jul;72(1):151-158. (IF=10.190, Corresponding Author)
21. Ghofrani H-A, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, Jenkins DP, **Jing ZC**, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH, on behalf of the MERIT study investigators. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind,

placebo-controlled study. *Lancet Respir Med*. 2017 Oct;5(10):785-794.

(IF=30.700, Steering Committee Member of this Global study)

22. Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, **Jing ZC**, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease (PVD) Through a Precision Medicine Approach. A Joint NHLBI-CMREF Workshop Report. *Am J Respir Crit Care Med*. 2017 Jun 15;195(12):1661-1670. **(IF=21.405, invited Committee Member)**
23. Liu D, Yan Y, Chen JW, Yuan P, Wang XJ, Jiang R, Wang L, Zhao QH, Wu WH, Simonneau G, Qu JM, **Jing ZC**. Hypermethylation of BMPR2 Promoter Occurs in the Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. *Am J Respir Crit Care Med*. 2017 Oct 1;196(7):925-928. **(IF=21.405, Corresponding Author)**
24. Zhang R, Wang XJ, Zhang HD, Sun XQ, Zhao QH, Wang L, He J, Jiang X, Liu JM, **Jing ZC**. Profiling nitric-oxide metabolites in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2016 Nov;48(5):1386-1395 **(IF=16.671, Corresponding Author)**
25. Ghofrani HA, Grimminger F, Grunig E, Huang Y, Jansa P, **Jing ZC**, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomized long-term extension trial. *Lancet Respir Med*. 2016 May;4(5):361-371. **(IF=30.700, Co-author)**
26. Liu D, Wu BX, Sun N, Yan Y, Yuan P, Qu JM, **Jing ZC**. Elevated levels of circulating BMP7 predict mortality in pulmonary arterial hypertension. *Chest*. 2016 Aug;150(2):367-73. **(IF=9.410, Corresponding Author)**

27. Hoeper M, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, **Jing ZC**, Gibbs JS R. A global view of pulmonary hypertension. *Lancet Respir Med.* 2016 Apr;4(4):306-322. (IF=30.700, Co-author in this invited review)
28. Evans JD, Girerd B, Montani D, Wang XJ, Austin ED, Elliott G, Asano K, Grunig E, Yan Y, **Jing ZC**, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Graf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. *Lancet Respir Med.* 2016 Feb;4(2):129-137. (IF=30.700, Co-author)
29. Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, Liu QQ, Wang L, Zhao QH, He J, **Jing ZC**. Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension. *Am J Cardiol.* 2014 Nov 1;114(9):1420-1425. (IF=2.778, Corresponding Author)
30. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, **Jing ZC**, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. *J Am Coll Cardiol.* 2014 Oct;42 Suppl 1:78-94. (IF=24.094, Co-Task Force Committee member, this article is WHO Guideline)
31. Pulido T, Adzerikho I, Channick R, Delcroix M, Galie N, Chofrani HA, Jansa P, **Jing ZC**, Le Brun FO, Mehta S, Mittelholzer C, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng XF, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. *N Engl J Med.* 2013 Aug 29;369(9):809-818. (IF=94.444, Steering Committee Member of this Global study)
32. Fan YF, Zhang R, Jiang X, Wen L, Wu DC, Liu D, Yuan P, Wang YL, **Jing ZC**. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. *Cardiovasc Res.* 2013 Aug 1;99(3):395-403. (IF=10.787, Corresponding Author)

33. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, **Jing ZC**, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, and Rubin LJ, for the PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2013 Jul 25;369(4):330-340. (IF=94.444, **Co-author, Steering Committee Member of this Global study**)
34. **Jing ZC**, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Arneson C, Laliberte K, and Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial. *Circulation*. 2013 Feb 5;127(5):624-633. (IF=26.690, **1st and Corresponding Author**)
35. Wu WH, Yang L, Peng FH, Yao J, Zou LL, Liu D, Jiang X, Li J, Gao L, Qu JM, Kawut SM, **Jing ZC**. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2013 Feb 1;187(3):303-310 (IF=21.405, **Corresponding Author**)
36. Yuan P, Wu WH, Gao L, Zheng ZQ, Liu D, Mei HY, Zhang ZL, **Jing ZC**. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, PGI2 and ET-1 pathways. *Eur Respir J*. 2013 May;41(5):1116-1125. (IF=16.671, **Corresponding Author**)
37. Berger RMF, Beghetti M, Humpl T, Raskob GE, Ivy DD, **Jing ZC**, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a registry study. *Lancet*. 2012 Feb 11;379(9815):537-546. (IF=79.321, **Co-author**)
38. Zhang ZN, Jiang X, Zhang R, Li XL, Wu BX, Zhao QH, Wang Y, Dai LZ, Pan L, Gomberg-Maitland M, **Jing ZC**. Oral Sildenafil therapy for Eisenmenger Syndrome: A prospective, open-label, multicenter study. *Heart*. 2011 Nov;97(22):1876-1881. (IF=5.994, **Corresponding Author**)
39. Sun PY, Jiang X, Gomberg-Maitland M, Zhao QH, He J, Yuan P, Zhang R, **Jing ZC**. Prolonged QRS Duration: A New Predictor of Adverse Outcome in Idiopathic Pulmonary Arterial Hypertension. *Chest*. 2012 Feb;141(2):374-380. (IF=9.410, **Corresponding Author**)

40. Liu D, Liu QQ, Melanie E, Wu WH, Yuan P, Zhang R, Soubrier F, **Jing ZC**. Molecular Genetics and Clinical Features of Chinese IPAH and HPAH Patients. *Eur Respir J*. 2012 Mar;39 (3):597-603 (IF=16.671, Corresponding Author)
41. **Jing ZC**, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè N for the Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study. Vadenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study. *Am J Respir Crit Care Med*. 2011 Jun 15;183(12):1723-1729. (IF=21.405, 1st and Corresponding Author)
42. Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, Yuan P, Jiang X, He J, Humbert M, **Jing ZC**. Survival of Chinese Patients with Pulmonary Arterial Hypertension in the Modern Management Era. *Chest*. 2011 Aug;140(2):301-309. (IF=9.410, Corresponding Author)
43. **Jing ZC**, Strange G, Zhu XY, Zhou DX, Shen JY, Gu H, Yang ZK, Pan X, Xiang MX, Yao H, Zhao DB, Dalton BS, Zhang ZL, Wang Y, Cheng XS, Yang YJ. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. *J Heart Lung Transplant*. 2010 Feb;29(2):150-156. (IF=10.247, 1st and Corresponding Author)
44. **Jing ZC**, Jiang X, Wu BX, Xu XQ, Wu Y, Ma CR, Wang Y, Yang YJ, Pu JL, Gao W. Vardenafil Therapy for Patients with Pulmonary Arterial Hypertension: a multicentre open-label study. *Heart*. 2009 Sep;95:1531-1536. (IF=5.994, 1st and Corresponding Author)
45. Xu XQ, **Jing ZC**. High-altitude pulmonary hypertension. *Eur Respir Rev*. 2009 Mar 1;18(111):13-17. (IF=8,839, Corresponding Author)
46. **Jing ZC**, Jing X, Han ZY, Xu XQ, Wang Y, Wu Y, Lv H, Ma CR, Yang YJ, Pu JL. Iloprost for Pulmonary Vasodilator Testing in Idiopathic Pulmonary Arterial Hypertension. *Eur Respir J*. 2009 Jun; 33:1354-1360. (IF=16.671, 1st and Corresponding Author)
47. Simonneau G, Robbins IM, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, **Jing ZC**, Krowka MJ, Langleben D, Nakanishi N, Souza

- R. Updated Clinical Classification of Pulmonary Hypertension. *J Am Coll Cardiol*. 2009 Jun 30;54(1):S43-S54. (IF=24.094, Co-Committee Member, this article is WHO guideline)
48. **Jing ZC**, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS, Hui RT, Yang YJ. Registry and survival study of Chinese patients with idiopathic and familial pulmonary arterial hypertension. *Chest*. 2007 Aug;132:373-379. (IF=9.410, 1st and Corresponding Author)
49. Hoepfer MM, Lee SH, Vosswinkel R, Galie N, Jais X, Manes A, Barst RJ, Ghofrani HA, **Jing ZC**, Opitz C, Seyfarth HJ, Halank M, Oudiz Ron, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. Complications of Right Heart Catheterization Procedures in patients with Pulmonary Hypertension. *J Am Coll Cardiol*. 2006 Dec 19;48(12):2546-2552. (IF=24.094, Co-author)
50. **Jing ZC**, Lu LH, Han ZY, Cheng XS, Zou YB, Yang YJ, Hui RT. Bone Morphogenetic Protein Receptor-2 Mutation Arg491Trp causes malignant phenotype of Familial Primary Hypertension. *Biochem Biophys Res Commun*. 2004 Mar 19;(315):1033-1038. (IF=3.575, 1st Author)

五、博士后招收研究方向及基本要求

1. 研究方向

- (1) 肺循环和先天性心脏病
- (2) 肺动脉高压与右心、右心瓣膜、左右心相互作用
- (3) 血栓形成、肺栓塞

2. 招收要求

身心健康，勤劳刻苦，具有较强的工作责任心、良好的学术道德和团队合作精神。能独立开展科学研究。

六、博士后相关待遇

1. 年薪 30 万起（税前，含五险一金）。
2. 另发住房补贴 4000 元/月。
3. 博士后启动经费 5 万元，中期考核合格者追加 3-5 万元科研经费。
4. 根据个人需要，可协助办理个人落户。
5. 鼓励并支持博士后申请各类博士后基金项目和人才计划，参加国际学术交流(境外交流项目)，助力青年人才成长和发展。
6. 鼓励并支持博士后独立申报国家、省部级基金以及广东省的各类博士后人才项目。
7. 获得国自然项目者按资助金额进行 1:1 进行配套，导师可另外提供丰厚科研经费。
8. 导师根据博士后工作情况，额外提供科研绩效奖励。

七、博士后岗位职责

1. 立足合作导师研究方向，独立开展科学研究并撰写学术论文；
2. 协助合作导师完成科研项目、指导研究生，参与课题组实验室的建设与管理工作；
3. 积极申报博士后科学基金、国家自然科学基金、广东省及广州市各级科研项目

八、应聘材料

1. 个人简历（含教育背景、科研背景、研究特长）；
2. 学历证书、学位证书、获奖证书等复印件；
3. 两名推荐人（包括博士生导师）的推荐信 2 封；
4. 博士论文、代表性论文等学术成果证明材料复印件；

5. 进站后工作设想（3000 字左右）。

九、联系方式

有意向者将应聘材料发送至如下邮箱，邮件主题请注明“博士后应聘”。

E-mail: jingzhicheng@vip.163.com

联系老师：荆志成

联系电话：020-83827812-10289